Nasus Pharma Ltd

Forward Looking Statements

****This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: the belief that the full analysis from the Phase 2 clinical study demonstrates NS002’s superior epinephrine delivery compared to traditional epinephrine autoinjectors; the belief that NS002 has the potential to become a leading product in anaphylaxis treatment; the expectation that the top line data from the Phase 2 study will support advancement of NS002 toward a pivotal study and future marketing applications; the potential of NS002 to exceed EpiPen® performance across the full spectrum of real-world conditions, including the challenging NAC environment that simulates scenarios patients may encounter during actual allergic reactions and, the timing of initiating its pivotal clinical study in the fourth quarter of 2026 . Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Registration Statement on Form F-1 filed with the U.S. Securities and Exchange Commission on March 2, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.